[1] BARTSCH P,SWENSON ER. Clinical practice:acute high-altitude illnesses[J].N Engl J Med, 2013, 368(24):2294-2302.
[2] SCHNEIDER M, BERNASCH D, WEYMANN J, et al. Acute mountain sickness:influence of susceptibility, preexposure, and ascent rate[J].Med Sci Sports Exerc, 2002, 34(12):1886-1891.
[3] FIORE DC, HALL S,SHOJA P. Altitude illness:risk factors, prevention, presentation, and treatment[J].Am Fam Physician, 2010, 82(9):1103-1110.
[4] KAYSER B,VERGES S. Hypoxia, energy balance and obesity:from pathophysiological mechanisms to new treatment strategies[J].Obes Rev, 2013, 14(7):579-592.
[5] ROACH RC, HOUSTON CS, HONIGMAN B, et al. How well do older persons tolerate moderate altitude[J].West J Med, 1995, 162(1):32-36.
[6] RI-LI G, CHASE PJ, WITKOWSKI S, et al. Obesity:associations with acute mountain sickness[J].Ann Intern Med, 2003, 139(4):253-257.
[7] HIRATA K, MASUYAMA S,SAITO A. Obesity as risk factor for acute mountain sickness[J].Lancet,1989,2(8670):1040-1041.
[8] MCDEVITT M, MCINTOSH SE, RODWAY G, et al. Risk determinants of acute mountain sickness in trekkers in the Nepali Himalaya:a 24-year follow-up[J].Wilderness Environ Med, 2014, 25(2):152-159.
[9] WU TY, DING SQ, LIU JL, et al. Who should not go high:chronic disease and work at altitude during construction of the Qinghai-Tibet railroad[J].High Alt Med Biol, 2007, 8(2):88-107.
[10] YANG B, SUN ZJ, CAO F, et al. Obesity is a risk factor for acute mountain sickness:a prospective study in Tibet railway construction workers on Tibetan plateau[J].Eur Rev Med Pharmacol Sci, 2015, 19(1):119-122.
[11] GAILLARD S, DELLASANTA P, LOUTAN L, et al. Awareness, prevalence, medication use, and risk factors of acute mountain sickness in tourists trekking around the Annapurnas in Nepal:a 12-year follow-up[J].High Alt Med Biol, 2004, 5(4):410-419.
[12] WAGNER DR, FARGO JD, PARKER D, et al. Variables contributing to acute mountain sickness on the summit of Mt Whitney[J].Wilderness Environ Med, 2006, 17(4):221-228.
[13] HIGGINS JP,THOMPSON SG. Quantifying heterogeneity in a meta-analysis[J].Stat Med, 2002, 21(11):1539-1558.
[14] GERTSCH JH, LIPMAN GS, HOLCK PS, et al. Prospective, double-blind, randomized, placebo-controlled comparison of acetazolamide versus ibuprofen for prophylaxis against high altitude headache:the Headache Evaluation at Altitude Trial (HEAT)[J].Wilderness Environ Med, 2010, 21(3):236-243.
[15] GERTSCH JH, CORBETT B, HOLCK PS, et al. Altitude sickness in climbers and efficacy of NSAIDs trial (ASCENT):randomized, controlled trial of ibuprofen versus placebo for prevention of altitude illness[J].Wilderness Environ Med, 2012, 23(4):307-315.
[16] LIPMAN GS, KANAAN NC, HOLCK PS, et al. Ibuprofen prevents altitude illness:a randomized controlled trial for prevention of altitude illness with nonsteroidal anti-inflammatories[J].Ann Emerg Med, 2012, 59(6):484-490.
[17] HSU TY, WENG YM, CHIU YH, et al. Rate of ascent and acute mountain sickness at high altitude[J].Clin J Sport Med, 2015, 25(2):95-104.
[18] WANG SH, CHEN YC, KAO WF, et al. Epidemiology of acute mountain sickness on Jade Mountain, Taiwan:an annual prospective observational study[J].High Alt Med Biol, 2010, 11(1):43-49.